Clinical Trial Detail

NCT ID NCT03582475
Title Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

prostate neuroendocrine neoplasm

urethra cancer

prostate small cell carcinoma

ureter small cell carcinoma

urinary bladder small cell neuroendocrine carcinoma

Therapies

Etoposide

Carboplatin + Docetaxel + Etoposide + Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab

Pembrolizumab

Carboplatin + Etoposide + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.